Categories: News

Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2022 financial results after the Nasdaq Global Market closes on Tuesday, August 2, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2022 financial results and to provide a corporate update.

The event will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

Staff

Recent Posts

Apollo Biowellness, Inc. Re-Files Application with OTCMarkets.com

North Bergen, New Jersey--(Newsfile Corp. - July 3, 2025) - Apollo Biowellness, Inc. (OTC Pink:…

44 minutes ago

AAMI Aligns With National Academy of Medicine AI Code of Conduct

AI Code of Conduct’s six core principles key to ensuring the safe and effective use…

2 hours ago

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0)…

2 hours ago

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

DELRAY BEACH, Fla., July 03, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS)…

2 hours ago

Only Transparency and Accountability Can Save CERN: Stop Billions in Waste, Unlock Life-Saving Innovations

DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- The Crosetto Foundation for the Reduction of Cancer…

2 hours ago